Market structure
FDA still frames the U.S. TNF blocker class around Remicade, Enbrel, Humira, Cimzia and Simponi, but the 2026 market is no longer one uniform competitive field: adalimumab is deeply biosimilarized, infliximab is a mature multi-brand infusion market with a separate subcutaneous maintenance brand, etanercept is regionally split, certolizumab remains comparatively insulated in the reviewed sources, and golimumab is already in biosimilar transition in Europe. 123456
View the TNF product landscape:
At a class level, that means TNF planning in 2026 is less about mechanism and more about molecule-by-molecule execution: which products have active biosimilar competition, which have route optionality, which remain originator-led, and which are entering the next wave of regional approvals. This article therefore treats the class as five distinct product environments rather than one monolithic market. The second sentence is an inference from the cited sources. 2346
| Molecule | Key products in source set | U.S. biosimilar depth shown in source set | Key 2026 readout |
|---|---|---|---|
| Adalimumab | Humira plus multiple biosimilars | Dense field; reviewed FDA materials identify 10 U.S. Humira biosimilar brands | Competition is now about interchangeable status, concentration and device formats |
| Infliximab | Remicade, Inflectra, Renflexis, Ixifi, Avsola, Zymfentra | Four IV biosimilars plus a separate SC maintenance brand | Only TNF franchise in this review with a clear IV-to-SC continuum |
| Etanercept | Enbrel, Erelzi, Eticovo | Approved biosimilars exist, but reviewed U.S. Purple Book entries show discontinued marketing status | The U.S. and EU landscapes diverge sharply |
| Certolizumab pegol | Cimzia | No biosimilar competition identified in the reviewed source set | Still commercially insulated despite loss of patent protection noted by UCB |
| Golimumab | Simponi, Simponi Aria, Gotenfia | U.S. pressure is pending in the reviewed official materials; EU biosimilar entry exists | Likely the next major TNF transition area |
Adalimumab dominates
By breadth of competition, adalimumab is the class center of gravity. The FDA materials reviewed here identify ten current U.S. Humira biosimilar brands: Amjevita, Abrilada, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma and Yusimry. The same materials show that competition is now being fought at the presentation level as well, with a mix of interchangeable designations, high-concentration formats and autoinjector or syringe options; the Purple Book snapshot also includes a Hadlima 80 mg/0.8 mL autoinjector entry licensed on April 29, 2026. 278
Europe is broader again. Late-2025 EMA PRAC materials referenced Humira plus Amgevita, Amsparity, Hefiya, Hukyndra, Hulio, Hyrimoz, Idacio, Imraldi, Libmyris and Yuflyma, underscoring that EU adalimumab competition is already highly multi-brand. AbbVie’s 2025 Form 10-K reports Humira net revenues of $4.54 billion and states that Humira net revenues decreased 49% in 2025, consistent with a market that has moved beyond the initial U.S. loss-of-exclusivity event into a structurally different revenue base. The last clause is an inference from AbbVie’s reported figures. 910
Infliximab keeps evolving
Infliximab is the next-most developed TNF biosimilar arena in the U.S. FDA Purple Book entries show Remicade as the reference product and four U.S. biosimilars—Inflectra, Renflexis, Ixifi and Avsola—approved as intravenous 100 mg single-dose vial products. Unlike adalimumab, the core competitive geometry here is not device variety but multi-brand substitution within a standardized hospital or infusion-center format. The last sentence is an inference from the reviewed product presentations. 1112131415
Infliximab also has the clearest route expansion in the current source set. The FDA label for Zymfentra identifies subcutaneous infliximab-dyyb as a maintenance option for adults with moderately to severely active ulcerative colitis and Crohn’s disease after intravenous infliximab induction, with dosing beginning at week 10 and then every two weeks. That creates an IV-to-SC continuum that none of the other TNF molecules in this review replicate as clearly. The last sentence is an inference from the reviewed label and class map. 3
Commercially, J&J reported 2025 Remicade sales of $1.768 billion, up 10.2%, and said the increase reflected favorable patient mix, market growth and the return of certain European rights, partially offset by continued biosimilar competition. Europe also remains a live infliximab biosimilar market in official EMA materials, which maintain separate EPARs for Inflectra, Flixabi and Zessly alongside Remicade. 16171819
The rest of the class is on different timelines
Etanercept is the clearest case of U.S.-EU divergence. In the U.S., FDA Purple Book pages for Erelzi and Eticovo show approved etanercept biosimilars, but all listed presentations carry discontinued marketing status. Amgen nevertheless reported 2025 Enbrel sales of $2.226 billion, down 33%, indicating that the originator still anchors the U.S. etanercept business in the source set reviewed here. EMA materials, by contrast, continue to reference Benepali, Erelzi and Nepexto, showing a broader established biosimilar picture in Europe. 4202122
Certolizumab pegol remains unusually insulated for a mature TNF product. The current FDA label supports Cimzia across rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, Crohn’s disease and plaque psoriasis. UCB reported 2025 Cimzia net sales of €1.954 billion and said that, although Cimzia has not been patent protected in the U.S. and EU since 2024, there is no biosimilar competition today and none expected near term. 235
Golimumab is the next transition story rather than the most mature one. In the EU, EMA has authorized Gotenfia as a biosimilar to Simponi, while the EMA Simponi page shows a broad golimumab label that includes rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, adult and pediatric ulcerative colitis, and polyarticular juvenile idiopathic arthritis. In the U.S., J&J reported 2025 sales of $2.668 billion for Simponi/Simponi Aria and stated that at least two biosimilars are pursuing regulatory approval for a Simponi biosimilar in the United States. That pattern suggests Europe is already in golimumab biosimilar implementation while the U.S. remains in the pre-launch phase within the reviewed materials. The last sentence is an inference from the cited sources. 62416
Planning implications
Access has become product-specific rather than molecule-specific. Express Scripts’ 2026 National Preferred Formulary names adalimumab-adaz, adalimumab-adbm, adalimumab-ryvk by Quallent and Simlandi among preferred inflammatory-condition options, while the companion exclusion materials list many other adalimumab products, including Humira, Abrilada, Amjevita, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma and Yusimry. UnitedHealthcare’s 2026 commercial PDL likewise places adalimumab-adaz and Amjevita in Tier 2 and marks Humira with additional utilization-management notation. 2526
Headline safety framing remains class-consistent. FDA labeling for Remicade, Enbrel and Simponi continues to warn about serious infections and malignancy, and EMA pages for Simponi and Gotenfia describe serious infection risks including tuberculosis, pneumonia and sepsis, as well as hepatitis B reactivation, demyelinating disorders, heart failure, lymphoma and leukemia. For decision-makers, that keeps much of the practical differentiation outside the class-warning headline and inside route, device, indication fit, contracts and regional authorisation status. The last sentence is an inference from the reviewed sources. 272829246
The current source set does not specify real-time net pricing by channel, market share by indication, or comprehensive country-by-country launch depth, so those details are intentionally left unspecified here. Even with those limits, the directional map is clear: adalimumab is the densest TNF battleground, infliximab has the most route flexibility, etanercept is regionally split, certolizumab remains comparatively insulated, and golimumab is entering its next biosimilar phase. 23456